Jon Mauer, RPh, MBA

Executive Vice President, Strategy and Decision Science

Jon Mauer is a pharmaceutical strategy and decision science executive with more than 30 years of experience helping leaders make high-stakes decisions under uncertainty. A pharmacist by training, Jon integrates scientific, commercial, regulatory, policy, and financial perspectives to help organizations determine where to invest, how to manage risk, and how to create value for patients and the business.

Before joining Lexidyne, Jon held leadership roles at Pfizer and Bristol Myers Squibb. His work has spanned product and portfolio strategy, quantitative benefit–risk assessment, clinical development, business development, forecasting and valuation, policy strategy and regulatory modernization, crisis management, evidence generation, and enterprise decision support. He has advised executives on decisions ranging from clinical development programs and licensing opportunities to portfolio investment, regulatory strategy, and major organizational choices.

Jon specializes in structuring complex decisions so that assumptions, uncertainties, tradeoffs, and stakeholder values become explicit. He has designed and applied decision-analysis frameworks, probabilistic models, scenario analyses, multi-criteria decision methods, and portfolio tools across the pharmaceutical lifecycle. His capabilities include Bayesian probability-of-success modeling and clinical trial simulation, helping teams translate emerging evidence into better development and investment decisions.

Jon has authored peer-reviewed research demonstrating how patient evidence, quantitative benefit–risk analysis, and structured decision methods can improve high-stakes product-development and regulatory decisions.

At Lexidyne, Jon integrates decision science with the firm’s advanced simulation, patient-flow modeling, analytics, and artificial intelligence capabilities. This combination enables clients to move beyond forecasting what may happen—to understand why it may happen, what it means for their portfolios, and which actions offer the greatest strategic value.

Jon is an active leader in the decision-professional community and has published and presented on structured decision-making, quantitative benefit–risk assessment, and the integration of patient preferences into healthcare decisions.

The Lexidyne Team is Ready to Tackle Quintessential Problems in Your Organization

Kirk Solo

Kirk Solo

President and CEO

Robert Malone

Chief Technology Officer

Jon Mauer

Executive Vice President, Strategy and Decision Science

Brian Dawson

Executive Vice President, Market Analytics

Louisa Penrice

Director of Business Analytics

Lexidyne

Phoebe Porter

Director of Analytics and Epidemiology

Let Lexidyne Provide You With Unique Business Solutions and Expertise.
Quote
The team at Lexidyne includes some of the most knowledgeable, experienced, and capable system dynamics people you can find anywhere.

General Manager, Professional Services
Fortune 500 Company